Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467007 · ClinicalTrials.gov registry record · NA
Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
A NA study, sponsored by Andrew Meltzer.
- Completed
- Registry status
- NA
- Development phase
- 360
- Enrollment target
NCT05467007 is a NA study that has completed, run by Andrew Meltzer. The registered enrollment target is 360 participants.
The verdict
NCT05467007, a NA study, has completed, sponsored by Andrew Meltzer.
- COMPLETED
- Registry status
- NA
- Development phase
- 360 participants
- Enrollment target
Study Summary
Rapid diagnosis and precise treatment have become possible with multiplex polymerase chain reaction (PCR) panels that can identify a variety of causative agents of acute respiratory illnesses such as bacterial and viral infections in one urgent care visit. While real-time PCR is currently used as a standard for diagnosing acute respiratory illnesses such as influenza due to its high sensitivity and specificity, it typically takes several hours for results which is unfavorable in the urgent care setting. Highly sensitive and rapid random-access PCR tests provide the sensitivity and specificity needed to both rapidly and accurately diagnose acute respiratory illnesses. Similar PCR panels have been used in previous research for the diagnosis of gastrointestinal illnesses in the emergency department and point-of-care testing for hospitalized adults presenting with acute respiratory illness. In this study, the investigators aim to determine if a rapid multiplex PCR test for urgent care patients with symptomatic upper respiratory infections can improve patient and provider-reported outcomes. This study utilizes the Biofire® FilmArray Panel (RP2.1-EZ) which in previous studies has been shown to be highly effective in diagnosing acute respiratory illnesses.
Interventions
- DIAGNOSTIC_TEST BioFire® Respiratory Panel 2.1-EZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05467007
The ClinicalTrials.gov registry entry for NCT05467007 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew Meltzer, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BioFire® Respiratory Panel 2.1-EZ is the first listed.
NCT05467007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05467007 about?
NCT05467007 is a clinical study titled "Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway". Rapid diagnosis and precise treatment have become possible with multiplex polymerase chain reaction (PCR) panels that can identify a variety of causative agents of acute respiratory illnesses such as bacterial and viral infections in one urgent care visit. While real-time PCR is currently used as a ...
What is the current status of trial NCT05467007?
This trial is currently completed. It is a NA study. The enrollment target is 360 participants. The study started on 2022-04-04. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT05467007?
The interventions under investigation include: BioFire® Respiratory Panel 2.1-EZ (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05467007?
This trial is sponsored by Andrew Meltzer, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.